Salim Erkaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Salim Erkaya has a total of 293 co-authors. Here are the top co-authors by number of shared publications:
- Dilek Sahin
Perinatology Department Ankara Bilkent City Hospital Ankara Turkey
20 shared publications - Tayfun Güngör
Department of Stem Cell Transplantation, University Children's Hospital, Zürich, Switzerland
16 shared publications - Emre Ozgu
Department of Gynecologic Oncology, Zekai Tahir Burak Women Health Education and Research Hospital, Ankara, Turkey
14 shared publications - Ayse Seval Ozgu-Erdinc
Perinatology Department, University of Health Sciences Bilkent City Hospital, Türkiye
12 shared publications - Nafiye Yilmaz
University of Health Sciences, Ankara City Hospital
12 shared publications - Aytekin Tokmak
Kirikkale Universitesi
8 shared publications
Latest Publications
- 12 October 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
Relationship of the C‐reactive protein/albumin ratio and the albumin‐bilirubin score with latency period and perinatal outcomes in preterm premature rupture of membranes
Objective: This study aimed to evaluate the associations of the C‐reactive protein‐to‐albumin ratio (CAR index) and the albumin–bilirubin (ALBI) score with latency duration and adverse perinatal outcomes among patients with preterm premature rupture of membranes (PPROM). Materials and Methods: This was a single‐center, retrospective study conducted at a tertiary care center. This study included 218 singleton pregnancies followed by a diagnosis of PPROM before 34 weeks of gestation between January 2022 and December 2025. Patients were divided into three groups according to the latency period: delivery within the first 48 h ( n = 92, 42%—Group 1), delivery between 48 h and 7 days ( n = 56, 25.7%—Group 2), and delivery after 7 days ( n = 70, 32.1%—Group 3). First, the associations of the CAR index and ALBI score with latency period were evaluated across all three groups. Subsequently, the associations of the CAR index and ALBI score with neonatal outcomes were examined. Results: The CAR index was significantly higher in Groups 1 and 2 than in Group 3 ( P < 0.001). The CAR index showed discriminatory ability for delivery within 48 h and within 7 days, with sensitivities of 82.3% and 66.2%, respectively. In subgroup analysis, a higher maternal ALBI score was significantly associated with neonatal umbilical artery pH P = 0.004). Conclusion: In patients with PPROM, the CAR index was associated with shorter latency and showed discriminatory ability for delivery within the first 48 h and within the first 7 days, whereas a higher ALBI score was significantly associated with neonatal umbilical artery pH <7.20.
- 12 October 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
Relationship of the C‐reactive protein/albumin ratio and the albumin‐bilirubin score with latency period and perinatal outcomes in preterm premature rupture of membranes
Objective: This study aimed to evaluate the associations of the C‐reactive protein‐to‐albumin ratio (CAR index) and the albumin–bilirubin (ALBI) score with latency duration and adverse perinatal outcomes among patients with preterm premature rupture of membranes (PPROM). Materials and Methods: This was a single‐center, retrospective study conducted at a tertiary care center. This study included 218 singleton pregnancies followed by a diagnosis of PPROM before 34 weeks of gestation between January 2022 and December 2025. Patients were divided into three groups according to the latency period: delivery within the first 48 h ( n = 92, 42%—Group 1), delivery between 48 h and 7 days ( n = 56, 25.7%—Group 2), and delivery after 7 days ( n = 70, 32.1%—Group 3). First, the associations of the CAR index and ALBI score with latency period were evaluated across all three groups. Subsequently, the associations of the CAR index and ALBI score with neonatal outcomes were examined. Results: The CAR index was significantly higher in Groups 1 and 2 than in Group 3 ( P < 0.001). The CAR index showed discriminatory ability for delivery within 48 h and within 7 days, with sensitivities of 82.3% and 66.2%, respectively. In subgroup analysis, a higher maternal ALBI score was significantly associated with neonatal umbilical artery pH P = 0.004). Conclusion: In patients with PPROM, the CAR index was associated with shorter latency and showed discriminatory ability for delivery within the first 48 h and within the first 7 days, whereas a higher ALBI score was significantly associated with neonatal umbilical artery pH <7.20.
- 29 June 2026
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 54 (9) , 2105-2113
Cerebroplacental–Uterine Ratio Improves Prediction of Composite Adverse Perinatal Outcomes in Pregnancies Complicated by Maternal Anemia
Objective: To evaluate fetomaternal Doppler changes in pregnancies complicated by maternal anemia and to investigate the predictive value of the cerebroplacental–uterine ratio (CPUR) for composite adverse perinatal outcomes (CAPOs). Methods: This prospective case–control study included 203 singleton pregnancies at ≥ 28 weeks of gestation. Participants were categorized according to third‐trimester hemoglobin levels as moderate anemia (hemoglobin 6–9 g/dL, n = 23), mild anemia (hemoglobin 9–11 g/dL, n = 41), and non‐anemic controls (hemoglobin ≥ 11 g/dL, n = 139). Umbilical artery pulsatility index (UA‐PI), middle cerebral artery pulsatility index (MCA‐PI), and uterine artery pulsatility index (UtA‐PI) were measured. The cerebroplacental ratio (CPR) was calculated as MCA‐PI/UA‐PI, and CPUR was calculated as CPR/mean UtA‐PI. CAPO was defined as the presence of at least one of the following: preterm birth, low birth weight, small for gestational age, low fifth‐minute Apgar score, abnormal umbilical artery cord blood gas values, or neonatal intensive care unit admission. Results: Women with moderate anemia had significantly lower gestational age at birth, lower birth weight, lower first‐ and fifth‐minute Apgar scores, and worse umbilical artery cord blood gas parameters than controls. The prevalence of small for gestational age neonates, neonatal intensive care unit admission, and CAPO increased progressively with anemia severity. UA‐PI and UtA‐PI were significantly higher, whereas CPR and CPUR were significantly lower in pregnancies complicated by moderate anemia. Hemoglobin alone showed moderate predictive performance for CAPO prediction (AUC = 0.724, 95% CI: 0.643–0.801, p < 0.001). CPUR demonstrated higher discriminative ability than CPR for predicting CAPO (AUC = 0.841 vs. 0.791, both p < 0.001). In multivariable logistic regression analysis, hemoglobin level, gestational age at birth, UA‐PI, UtA‐PI, and CPUR remained independent predictors of CAPO. Conclusion: Maternal anemia is associated with impaired uteroplacental and fetoplacental hemodynamics and increased adverse perinatal outcomes. CPUR demonstrates superior predictive performance compared with CPR and hemoglobin alone and may serve as a useful adjunctive Doppler marker in the surveillance of pregnancies complicated by maternal anemia.
- 29 June 2026
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 54 (9) , 2105-2113
Cerebroplacental–Uterine Ratio Improves Prediction of Composite Adverse Perinatal Outcomes in Pregnancies Complicated by Maternal Anemia
Objective: To evaluate fetomaternal Doppler changes in pregnancies complicated by maternal anemia and to investigate the predictive value of the cerebroplacental–uterine ratio (CPUR) for composite adverse perinatal outcomes (CAPOs). Methods: This prospective case–control study included 203 singleton pregnancies at ≥ 28 weeks of gestation. Participants were categorized according to third‐trimester hemoglobin levels as moderate anemia (hemoglobin 6–9 g/dL, n = 23), mild anemia (hemoglobin 9–11 g/dL, n = 41), and non‐anemic controls (hemoglobin ≥ 11 g/dL, n = 139). Umbilical artery pulsatility index (UA‐PI), middle cerebral artery pulsatility index (MCA‐PI), and uterine artery pulsatility index (UtA‐PI) were measured. The cerebroplacental ratio (CPR) was calculated as MCA‐PI/UA‐PI, and CPUR was calculated as CPR/mean UtA‐PI. CAPO was defined as the presence of at least one of the following: preterm birth, low birth weight, small for gestational age, low fifth‐minute Apgar score, abnormal umbilical artery cord blood gas values, or neonatal intensive care unit admission. Results: Women with moderate anemia had significantly lower gestational age at birth, lower birth weight, lower first‐ and fifth‐minute Apgar scores, and worse umbilical artery cord blood gas parameters than controls. The prevalence of small for gestational age neonates, neonatal intensive care unit admission, and CAPO increased progressively with anemia severity. UA‐PI and UtA‐PI were significantly higher, whereas CPR and CPUR were significantly lower in pregnancies complicated by moderate anemia. Hemoglobin alone showed moderate predictive performance for CAPO prediction (AUC = 0.724, 95% CI: 0.643–0.801, p < 0.001). CPUR demonstrated higher discriminative ability than CPR for predicting CAPO (AUC = 0.841 vs. 0.791, both p < 0.001). In multivariable logistic regression analysis, hemoglobin level, gestational age at birth, UA‐PI, UtA‐PI, and CPUR remained independent predictors of CAPO. Conclusion: Maternal anemia is associated with impaired uteroplacental and fetoplacental hemodynamics and increased adverse perinatal outcomes. CPUR demonstrates superior predictive performance compared with CPR and hemoglobin alone and may serve as a useful adjunctive Doppler marker in the surveillance of pregnancies complicated by maternal anemia.
- 30 April 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 175 (1) , 445-452
Systemic inflammatory indices as predictors of adverse outcomes in pregnancies with vascular events: A retrospective cohort study
Objective: To investigate the association between systemic inflammatory indices, including the systemic immune‐inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI), and vascular events during pregnancy, and to evaluate their association with maternal disease severity, particularly maternal intensive care unit (ICU) requirement. Methods: This retrospective cohort study included pregnant and postpartum women with vascular events and gestational age–matched controls without vascular events. Inflammatory indices were calculated using first‐trimester laboratory parameters and values obtained at the time of vascular event diagnosis. Group comparisons were performed using non‐parametric tests, and receiver operating characteristic (ROC) curve analyses were conducted to assess the predictive performance of inflammatory indices for maternal ICU requirement. Results: First‐trimester inflammatory indices (SII‐1, SIRI‐1, and AISI‐1) and delta (Δ) values did not differ significantly between groups. In contrast, inflammatory indices measured at the time of vascular event diagnosis (SII‐2, SIRI‐2, and AISI‐2) were significantly higher in women who experienced vascular events. These indices were not associated with composite adverse perinatal outcomes (CAPO), neonatal intensive care unit (NICU) admission, or maternal sequelae. However, all three indices were significantly associated with maternal ICU requirement. Among them, SIRI‐2 demonstrated the strongest discriminatory performance for predicting maternal ICU admission (area under the curve: 0.911). Conclusion: Systemic inflammatory indices measured at the time of vascular event diagnosis may be associated with maternal disease severity but not with adverse perinatal outcomes; however, further prospective studies are needed to confirm their clinical utility.
- 30 April 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 175 (1) , 445-452
Systemic inflammatory indices as predictors of adverse outcomes in pregnancies with vascular events: A retrospective cohort study
Objective: To investigate the association between systemic inflammatory indices, including the systemic immune‐inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI), and vascular events during pregnancy, and to evaluate their association with maternal disease severity, particularly maternal intensive care unit (ICU) requirement. Methods: This retrospective cohort study included pregnant and postpartum women with vascular events and gestational age–matched controls without vascular events. Inflammatory indices were calculated using first‐trimester laboratory parameters and values obtained at the time of vascular event diagnosis. Group comparisons were performed using non‐parametric tests, and receiver operating characteristic (ROC) curve analyses were conducted to assess the predictive performance of inflammatory indices for maternal ICU requirement. Results: First‐trimester inflammatory indices (SII‐1, SIRI‐1, and AISI‐1) and delta (Δ) values did not differ significantly between groups. In contrast, inflammatory indices measured at the time of vascular event diagnosis (SII‐2, SIRI‐2, and AISI‐2) were significantly higher in women who experienced vascular events. These indices were not associated with composite adverse perinatal outcomes (CAPO), neonatal intensive care unit (NICU) admission, or maternal sequelae. However, all three indices were significantly associated with maternal ICU requirement. Among them, SIRI‐2 demonstrated the strongest discriminatory performance for predicting maternal ICU admission (area under the curve: 0.911). Conclusion: Systemic inflammatory indices measured at the time of vascular event diagnosis may be associated with maternal disease severity but not with adverse perinatal outcomes; however, further prospective studies are needed to confirm their clinical utility.
- 29 August 2025
- Published by Medical Journal of Ankara Training and Research Hospital in Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi
- Vol. 58 (2) , 66-70
Can the Systemic Immune-Inflammation Index (SII) Predict the Outcome of Threatened Miscarriage?
Aim: Inflammatory markers have gained attention in recent years and the search continues for cost-effective, widely available, easily applicable, and interpretable biomarkers that can more accurately predict pregnancy outcomes. The study aims to determine a cut-off value for systemic immune-inflammation index (SII) (neutrophil × platelet /lymphocyte) in the prediction of the outcome of threatened miscarriage (TM). Materials and Methods: This retrospective case-control study was designed at the Obstetrics-Gynecology and Perinatology Clinics. Singleton pregnant women with TM who were followed up in the outpatient clinics or hospitalized and whose pregnancy resulted in our hospital were included in the study. Women whose pregnancies resulted in miscarriage were included in Group I. Women whose pregnancies resulted in childbirth were in Group II. Receiver operating characteristic (ROC) curves were used to assess the performance of inflammatory indexes in predicting the outcome of TM. Results: A total of 730 pregnant women with the diagnosis of TM were included in the present study. There were 239 patients in Group I and there were 491 patients in Group II. SII was statistically significantly higher in Group II (856.6 vs. 938.4; p
- 29 August 2025
- Published by Medical Journal of Ankara Training and Research Hospital in Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi
- Vol. 58 (2) , 66-70
Can the Systemic Immune-Inflammation Index (SII) Predict the Outcome of Threatened Miscarriage?
Aim: Inflammatory markers have gained attention in recent years and the search continues for cost-effective, widely available, easily applicable, and interpretable biomarkers that can more accurately predict pregnancy outcomes. The study aims to determine a cut-off value for systemic immune-inflammation index (SII) (neutrophil × platelet /lymphocyte) in the prediction of the outcome of threatened miscarriage (TM). Materials and Methods: This retrospective case-control study was designed at the Obstetrics-Gynecology and Perinatology Clinics. Singleton pregnant women with TM who were followed up in the outpatient clinics or hospitalized and whose pregnancy resulted in our hospital were included in the study. Women whose pregnancies resulted in miscarriage were included in Group I. Women whose pregnancies resulted in childbirth were in Group II. Receiver operating characteristic (ROC) curves were used to assess the performance of inflammatory indexes in predicting the outcome of TM. Results: A total of 730 pregnant women with the diagnosis of TM were included in the present study. There were 239 patients in Group I and there were 491 patients in Group II. SII was statistically significantly higher in Group II (856.6 vs. 938.4; p
- Open Access
- 4 May 2025
- Published by Medical Journal of Ankara Training and Research Hospital in Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi
- Vol. 58 (1) , 30-35
A comparison of maternal and neonatal outcomes in cases of pre-viable preterm premature rupture of membranes (pPPROM) according to weeks of gestation
Aim: The rupture of the amniotic membrane before 24 weeks gestation is defined as pre-viable preterm premature rupture of membranes (pPPROM). This study aims to compare the maternal and neonatal outcomes of cases of pPPROM detected before and after 22 weeks of gestation. Materials and Methods: This retrospective study evaluated singleton pregnancies with pPPROM between 2014 and 2019. The pPPROM cases were divided into two groups: Group 1 consisted of cases between 12+0 and 21+6 weeks of gestation, while Group 2 consisted of cases between 22+0 and 23+6 weeks of gestation. The obstetric outcomes, maternal complications, and neonatal intensive care unit (NICU) admission rates were compared in both groups. Furthermore, the neonatal outcomes of fetuses with a birth weight of over 500 grams were compared in both groups. Results: A total of 181 cases of pPPROM were identified, with 45 (24.8%) occurring in Group 2. The latent period duration, age at birth, and maternal complications were found to be higher in Group 2 (p < 0.05). Twenty percent of cases resulted in viable outcomes (15/136 vs. 22/45, p < 0.001). In Group 1, higher Apgar scores, lower rates of admission to NICU, and higher rates of pregnancy termination were observed in fetuses with a birth weight of over 500 grams (p < 0.05). Conclusion: In cases of pPPROM after the 22nd week of gestation, although the incidence of maternal morbidity is lower, the rate of admission to NICU is higher in fetuses born weighing over 500 grams.
- 4 May 2025
- Published by Medical Journal of Ankara Training and Research Hospital in Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi
- Vol. 58 (1) , 30-35
Open AccessA comparison of maternal and neonatal outcomes in cases of pre-viable preterm premature rupture of membranes (pPPROM) according to weeks of gestation
Aim: The rupture of the amniotic membrane before 24 weeks gestation is defined as pre-viable preterm premature rupture of membranes (pPPROM). This study aims to compare the maternal and neonatal outcomes of cases of pPPROM detected before and after 22 weeks of gestation. Materials and Methods: This retrospective study evaluated singleton pregnancies with pPPROM between 2014 and 2019. The pPPROM cases were divided into two groups: Group 1 consisted of cases between 12+0 and 21+6 weeks of gestation, while Group 2 consisted of cases between 22+0 and 23+6 weeks of gestation. The obstetric outcomes, maternal complications, and neonatal intensive care unit (NICU) admission rates were compared in both groups. Furthermore, the neonatal outcomes of fetuses with a birth weight of over 500 grams were compared in both groups. Results: A total of 181 cases of pPPROM were identified, with 45 (24.8%) occurring in Group 2. The latent period duration, age at birth, and maternal complications were found to be higher in Group 2 (p < 0.05). Twenty percent of cases resulted in viable outcomes (15/136 vs. 22/45, p < 0.001). In Group 1, higher Apgar scores, lower rates of admission to NICU, and higher rates of pregnancy termination were observed in fetuses with a birth weight of over 500 grams (p < 0.05). Conclusion: In cases of pPPROM after the 22nd week of gestation, although the incidence of maternal morbidity is lower, the rate of admission to NICU is higher in fetuses born weighing over 500 grams.
- Open Access
- 26 October 2024
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 5 (5) , 238-246
Indicators of prolonged hospital stay and rehospitalizations in hyperemesis gravidarum
Aims: Hyperemesis gravidarum (HG) can significantly impact the quality of life of pregnant women and is the primary factor leading to hospitalization during the first half of the pregnancy. The aim of this study is to determine the ability of basic laboratory indicators that determine the severity of HG and the indices that can be calculated from them to predict the total length of hospital stay and the number of recurrent hospitalizations. Methods: A retrospective analysis was conducted on women diagnosed with HG at a tertiary hospital from 2018 to 2021. Following the application of the inclusion criteria, we included a total of 100 eligible patients with HG (study group) and 130 healthy pregnant women (control group). Subsequently, the groups were subjected to a comparative analysis. Results: The study group had higher levels of hemoglobin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), red blood cell (RBC), white blood cells (WBC), neutrophil, mean platelet volüme (MPV), ketonuria, and lower levels of thyroid-stimulating hormone (TSH), eosinophil (p
- 26 October 2024
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 5 (5) , 238-246
Open AccessIndicators of prolonged hospital stay and rehospitalizations in hyperemesis gravidarum
Aims: Hyperemesis gravidarum (HG) can significantly impact the quality of life of pregnant women and is the primary factor leading to hospitalization during the first half of the pregnancy. The aim of this study is to determine the ability of basic laboratory indicators that determine the severity of HG and the indices that can be calculated from them to predict the total length of hospital stay and the number of recurrent hospitalizations. Methods: A retrospective analysis was conducted on women diagnosed with HG at a tertiary hospital from 2018 to 2021. Following the application of the inclusion criteria, we included a total of 100 eligible patients with HG (study group) and 130 healthy pregnant women (control group). Subsequently, the groups were subjected to a comparative analysis. Results: The study group had higher levels of hemoglobin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), red blood cell (RBC), white blood cells (WBC), neutrophil, mean platelet volüme (MPV), ketonuria, and lower levels of thyroid-stimulating hormone (TSH), eosinophil (p
- 22 January 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (2) , 1141-1149
Non-tubal ectopic pregnancy treatment experiences of a tertiary care center
Aim To evaluate the incidence, the risk factors, and the treatment outcomes of Non-tubal ectopic pregnancies (NTEP) treated in a tertiary care center. Material and methods A total of 110 NTEP cases treated between 2014 and 2019 were included in the retrospective study. The study cohort was divided into 6 groups according to the pregnancy localization: 87 cesarean scar pregnancies (CSPs), 7 ovarian pregnancies, 6 interstitial pregnancies, 4 rudimentary horn pregnancies, 4 abdominal pregnancies, and 2 cervical pregnancies. One woman rejected all treatment modalities. Demographic characteristics, treatment modalities, and outcomes of each group were evaluated. Results In the study cohort, expectant management was performed in one (0.9%) woman. The methotrexate (MTX) treatment was administered in 29 (26.3%) women. Seventeen (15.4%) women underwent surgery, and 63 (57.2%) women underwent manual vacuum aspiration (MVA). A woman rejected all treatment modalities. Although 70.1% (n = 61) of CSPs were cured with MVA, 24.1% (n = 21) of them were treated with a single-dose MTX regimen in addition to MVA. The higher mean gestational sac size (33,9 ± 12,96 mm vs. 17,34 ± 9,87 mm), the higher mean gestational week (8,43 ± 1,16w vs. 6,66 ± 1,49w), the presence of fetal heartbeat (FHB) (90.5% vs. 26,2%) and the history of pelvic ınflammatory disease (PID) (38.1% vs. 6,6%) were found in the CSPs with MVA treatment failure (p < 0.05). Conclusion The management of NTEPs should be individualized according to the clinical and ultrasonographic findings. The size of the ectopic pregnancy mass, the gestational week, the presence of FHB, and the PID history were the predictive factors for the failure of MVA in CSP cases.
- 22 January 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (2) , 1141-1149
Non-tubal ectopic pregnancy treatment experiences of a tertiary care center
Aim To evaluate the incidence, the risk factors, and the treatment outcomes of Non-tubal ectopic pregnancies (NTEP) treated in a tertiary care center. Material and methods A total of 110 NTEP cases treated between 2014 and 2019 were included in the retrospective study. The study cohort was divided into 6 groups according to the pregnancy localization: 87 cesarean scar pregnancies (CSPs), 7 ovarian pregnancies, 6 interstitial pregnancies, 4 rudimentary horn pregnancies, 4 abdominal pregnancies, and 2 cervical pregnancies. One woman rejected all treatment modalities. Demographic characteristics, treatment modalities, and outcomes of each group were evaluated. Results In the study cohort, expectant management was performed in one (0.9%) woman. The methotrexate (MTX) treatment was administered in 29 (26.3%) women. Seventeen (15.4%) women underwent surgery, and 63 (57.2%) women underwent manual vacuum aspiration (MVA). A woman rejected all treatment modalities. Although 70.1% (n = 61) of CSPs were cured with MVA, 24.1% (n = 21) of them were treated with a single-dose MTX regimen in addition to MVA. The higher mean gestational sac size (33,9 ± 12,96 mm vs. 17,34 ± 9,87 mm), the higher mean gestational week (8,43 ± 1,16w vs. 6,66 ± 1,49w), the presence of fetal heartbeat (FHB) (90.5% vs. 26,2%) and the history of pelvic ınflammatory disease (PID) (38.1% vs. 6,6%) were found in the CSPs with MVA treatment failure (p < 0.05). Conclusion The management of NTEPs should be individualized according to the clinical and ultrasonographic findings. The size of the ectopic pregnancy mass, the gestational week, the presence of FHB, and the PID history were the predictive factors for the failure of MVA in CSP cases.
- 26 July 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (6) , 2585-2590
Do the change in β-hCG values between the 0th and 4th days in tubal ectopic pregnancy treatment with a single-dose methotrexate (MTX) protocol predict the need for a second dose of MTX?
Aim The single-dose methotrexate (MTX) regimen is effective and minimizes side effects but an additional second dose is needed in case of failure in an ectopic pregnancy (EP). We aimed to predict the additional MTX dose by evaluating the change in β-hCG values between day 0 and day 4 in EPs with administered single-dose MTX regimen. Method A total of 454 tubal EPs between 2013 and 2019 were evaluated retrospectively. Cases cured with a single dose of MTX without an additional dose were accepted as the control group, and cases under a single-dose regimen were cured by applying a second dose of MTX on the 7th day were accepted as the study group. Obstetric and demographic characteristics and the change in β-hCG values compared in both groups. Results Age, body mass index (BMI), gravida, smoking, abdominal surgery, presence of IUDs, initial β-hCG levels (0th day), and EP size were similar in both groups, but the presence of previous EP history was significantly higher in the study group. The change of β-hCG from days 0 and 4 determined that a 20% increase predicts the need for a second dose of MTX with 72.4% sensitivity, and 87.8% negative predictive value (NPV). Conclusion The single-dose MTX protocol is successful in 83.3% of convenient cases (as the control group), but an increase of 20% in β-hCG between days 0 and 4 predicts the patients who need to be administered second-dose MTX, and thus, a double-dose MTX protocol will be achieved early.
- 26 July 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (6) , 2585-2590
Do the change in β-hCG values between the 0th and 4th days in tubal ectopic pregnancy treatment with a single-dose methotrexate (MTX) protocol predict the need for a second dose of MTX?
Aim The single-dose methotrexate (MTX) regimen is effective and minimizes side effects but an additional second dose is needed in case of failure in an ectopic pregnancy (EP). We aimed to predict the additional MTX dose by evaluating the change in β-hCG values between day 0 and day 4 in EPs with administered single-dose MTX regimen. Method A total of 454 tubal EPs between 2013 and 2019 were evaluated retrospectively. Cases cured with a single dose of MTX without an additional dose were accepted as the control group, and cases under a single-dose regimen were cured by applying a second dose of MTX on the 7th day were accepted as the study group. Obstetric and demographic characteristics and the change in β-hCG values compared in both groups. Results Age, body mass index (BMI), gravida, smoking, abdominal surgery, presence of IUDs, initial β-hCG levels (0th day), and EP size were similar in both groups, but the presence of previous EP history was significantly higher in the study group. The change of β-hCG from days 0 and 4 determined that a 20% increase predicts the need for a second dose of MTX with 72.4% sensitivity, and 87.8% negative predictive value (NPV). Conclusion The single-dose MTX protocol is successful in 83.3% of convenient cases (as the control group), but an increase of 20% in β-hCG between days 0 and 4 predicts the patients who need to be administered second-dose MTX, and thus, a double-dose MTX protocol will be achieved early.
- Open Access
- 22 September 2022
- Published by Turkish Journal of Womens Health and Neonatology, University of Health Sciences in Türk Kadın Sağlığı ve Neonatoloji Dergisi
- Vol. 4 (3) , 116-120
Gebeliğin Birinci ve İkinci Trimesterinde Görülen Vajinal Kanama ile Kötü Obstetrik Sonuçlar Arasındaki İlişki
Amaç: Abortus imminens 20.gestasyonel haftadan önce servikal değişiklikler olmaksızın vajinal kanama görülmesi olarak tanımlanır ve gebelik sonuçlarını etkileyen bir klinik durumdur. Çalışmamızın amacı abortus imminensin (Aİ) gebeliğin birinci veya ikinci trimesterinde izlenmesinin obstetrik sonuçlara etkisini araştırmaktır. Gereç ve Yöntem: Bu retrospektif çalışmaya Ocak 2017 ve Aralık 2019 yılları arasında erken gebelik servisine Aİ nedeniyle yatışı olan 831 tekil gebelik dahil edildi. Aİ tanısını aldığı gestasyonel haftaya göre olgular 1. ve 2. trimester (Grup 1 ve Grup 2) olmak üzere ikiye ayrılarak obstetrik sonuçlar karşılaştırıldı. Bulgular: Toplam 831 olgunun 622’si (%75,8) grup 1’e ve 209’u (%25,2) grup 2’ye ait idi. Grup 1’dekilerin %51,1’inde ve grup 2’dekilerin %44,2’sinde hematom mevcuttu (p=0,075). Gebeliğin sonlandığı gestasyonel hafta grup 2’dekilerde daha uzundu (33,04±8,8 karşın 28,14±13,94, p
- 22 September 2022
- Published by Turkish Journal of Womens Health and Neonatology, University of Health Sciences in Türk Kadın Sağlığı ve Neonatoloji Dergisi
- Vol. 4 (3) , 116-120
Open AccessGebeliğin Birinci ve İkinci Trimesterinde Görülen Vajinal Kanama ile Kötü Obstetrik Sonuçlar Arasındaki İlişki
Amaç: Abortus imminens 20.gestasyonel haftadan önce servikal değişiklikler olmaksızın vajinal kanama görülmesi olarak tanımlanır ve gebelik sonuçlarını etkileyen bir klinik durumdur. Çalışmamızın amacı abortus imminensin (Aİ) gebeliğin birinci veya ikinci trimesterinde izlenmesinin obstetrik sonuçlara etkisini araştırmaktır. Gereç ve Yöntem: Bu retrospektif çalışmaya Ocak 2017 ve Aralık 2019 yılları arasında erken gebelik servisine Aİ nedeniyle yatışı olan 831 tekil gebelik dahil edildi. Aİ tanısını aldığı gestasyonel haftaya göre olgular 1. ve 2. trimester (Grup 1 ve Grup 2) olmak üzere ikiye ayrılarak obstetrik sonuçlar karşılaştırıldı. Bulgular: Toplam 831 olgunun 622’si (%75,8) grup 1’e ve 209’u (%25,2) grup 2’ye ait idi. Grup 1’dekilerin %51,1’inde ve grup 2’dekilerin %44,2’sinde hematom mevcuttu (p=0,075). Gebeliğin sonlandığı gestasyonel hafta grup 2’dekilerde daha uzundu (33,04±8,8 karşın 28,14±13,94, p
- Open Access
- 21 September 2021
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- p. 1-5
Factor V H1299r (Hr2) Heterozygosity: A Risk Factor For Recurrent Implantation Failure Particularly In Non-Carriers For Factor V Leiden Mutation-A Case-Control Study
Objective: The association between recurrent implantation failure and thrombophilia is still controversial depending on the published reports with conflicting results. In this study, we aimed to assess the clinical relevance of screening women with recurrent implantation failure for some thrombophilic variants including factor V H1299R (FV HR2) haplotype. Study Design: A total of 279 women were recruited in this case-control study. 229 women with a history of recurrent implantation failure and 50 fertile control with no history of pregnancy losses were screened for eight specific gene mutations, regarding factor V G1691A gene (FV Leiden), FV HR2, factor II prothrombin G20210A, factor XIII V34L, PAI-1 4G/5G, MTHFR C677T, MTHFR A1298C and A3 haplotype of the endothelial cell protein C receptor gene. Results: Recurrent implantation failure group displayed a significantly higher prevalence of FV HR2 heterozygosity than fertile controls while the frequency of FV Leiden mutation was comparable between groups (p=0.011; p=0.619). Additionally, the difference in the prevalence of other specific or total gene mutations among women with recurrent implantation failure was also insignificant. Discussion: The primer outcome of this study was the co-existence of the higher prevalence of FV HR2 haplotype and the insignificant percentage of FV Leiden mutation in women with recurrent implantation failure. Thus, we emphasize that the HR2 haplotype may be associated with recurrent implantation failure particularly in non-carriers for FV Leiden mutation. In the necessity of screening for thrombophilia in recurrent implantation failure, HR2 haplotype should be involved in the searched gene panel particularly in the absence of FV Leiden mutation. Further large-scale prospective studies are needed to investigate whether screening or treatment for HR2 haplotype has any detrimental impact on implantation success in cases of recurrent implantation failure.
- 21 September 2021
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- p. 1-5
Open AccessFactor V H1299r (Hr2) Heterozygosity: A Risk Factor For Recurrent Implantation Failure Particularly In Non-Carriers For Factor V Leiden Mutation-A Case-Control Study
Objective: The association between recurrent implantation failure and thrombophilia is still controversial depending on the published reports with conflicting results. In this study, we aimed to assess the clinical relevance of screening women with recurrent implantation failure for some thrombophilic variants including factor V H1299R (FV HR2) haplotype. Study Design: A total of 279 women were recruited in this case-control study. 229 women with a history of recurrent implantation failure and 50 fertile control with no history of pregnancy losses were screened for eight specific gene mutations, regarding factor V G1691A gene (FV Leiden), FV HR2, factor II prothrombin G20210A, factor XIII V34L, PAI-1 4G/5G, MTHFR C677T, MTHFR A1298C and A3 haplotype of the endothelial cell protein C receptor gene. Results: Recurrent implantation failure group displayed a significantly higher prevalence of FV HR2 heterozygosity than fertile controls while the frequency of FV Leiden mutation was comparable between groups (p=0.011; p=0.619). Additionally, the difference in the prevalence of other specific or total gene mutations among women with recurrent implantation failure was also insignificant. Discussion: The primer outcome of this study was the co-existence of the higher prevalence of FV HR2 haplotype and the insignificant percentage of FV Leiden mutation in women with recurrent implantation failure. Thus, we emphasize that the HR2 haplotype may be associated with recurrent implantation failure particularly in non-carriers for FV Leiden mutation. In the necessity of screening for thrombophilia in recurrent implantation failure, HR2 haplotype should be involved in the searched gene panel particularly in the absence of FV Leiden mutation. Further large-scale prospective studies are needed to investigate whether screening or treatment for HR2 haplotype has any detrimental impact on implantation success in cases of recurrent implantation failure.